Condition: Liquid Biopsy · Melanoma (Skin) · Melanoma Stage III · Sponsor: Regina Elena Cancer Institute
The trial will test a paradigm-changing in vitro diagnostic device for Liquid Biopsy enabling facile simultaneous detection of protein and nucleic acid analytes with sensitivity at single-molecule level, e.g. not achievable with any alternative technology. A novel affinity-mediated transport amplification (AMT) method will be tested allowing for the multiplexed quantification of rare biomarkers circulating in blood. The Versilib AMT photonic biosensor will test two analytes: the known actionable DNA mutation BRAF p.V600E, and a melanoma-restricted protein antigen. The results will be compared to digital PCR and ELISA methods.
This description comes directly from the study's public registry record.
Elena Giordani, PhD · +39 06 5266 2533 · elena.giordani@ifo.it
Patrizio Giacomini, Doctor · +39 0652665054 · patrizio.giacomini@guest.policlinicogemelli.it
Always discuss trial participation with your own doctor first.
| "Regina Elena" National Cancer Institute | Rome, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05940311